Compare MRAM & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | IMRX |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.8M | 313.8M |
| IPO Year | 2016 | 2021 |
| Metric | MRAM | IMRX |
|---|---|---|
| Price | $14.61 | $4.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.50 | $17.20 |
| AVG Volume (30 Days) | ★ 956.1K | 613.9K |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.22 | N/A |
| Revenue Next Year | $7.38 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $7.35 | $3.86 |
| 52 Week High | $51.50 | $10.08 |
| Indicator | MRAM | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 35.69 |
| Support Level | $13.17 | $3.98 |
| Resistance Level | $15.93 | $5.32 |
| Average True Range (ATR) | 0.91 | 0.22 |
| MACD | -0.11 | -0.10 |
| Stochastic Oscillator | 1.66 | 7.79 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.